# Petros Pharmaceuticals, Inc. (PTPI)

> Source: Nexqual · https://nexqual.com/PTPI · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, Petros Pharmaceuticals, Inc. (PTPI), nexqual.com/PTPI" · informational, not investment advice.

**Price:** USD 0 (+0.00% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 0 · day 0–0 · 52w 0–0.02 · market cap $85K · PNK

## Key facts
- Analysts: None.
- Total return with dividends: 1Y -90.0% vs S&P 500 +13.4%; 5Y -100.0% vs S&P 500 +76.9%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $7.8M | $6.0M | $5.8M | $5.1M | — | — |
| Gross profit | $6.2M | $3.7M | $4.2M | $3.9M | — | — |
| Operating income | -$18.0M | -$19.9M | -$13.6M | -$4.6M | -$4.6M | -$3.4M |
| Net income | -$9.0M | -$20.0M | -$8.2M | -$14.3M | $1.9M | -$3.2M |
| EPS (diluted) | -$206.25 | -$242.00 | -$158.75 | -$83.47 | -$1.56 | — |
| Free cash flow | — | — | — | -$2.6M | — | — |
| Gross margin | 79.5% | 61.8% | 72.0% | 76.3% | — | — |
| Operating margin | -231.1% | -332.4% | -233.9% | -90.5% | — | — |
| Net margin | -115.0% | -334.4% | -140.2% | -280.1% | — | — |
| Revenue growth | -18.3% | -23.3% | -2.8% | -12.2% | — | — |
| Cash + short-term investments | $23.8M | $9.4M | $13.3M | $1.7M | $5.1M | — |
| Total debt | — | $8.4M | $6.9M | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 0.1x · Earnings yield -3778.31%
P/E at fiscal year-ends: Dec 2025 0.1x.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -90.0% | -100.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -90.1% | -91.5% |
| Volatility (annualized) | 198.8% | 164.1% |
| Max drawdown | -91.3% (Nov 2025→Oct 2026) | -100.0% (Dec 2021→Oct 2026) |

## Peers (Drug Manufacturers - Specialty & Generic)
SUPN (Supernus Pharmaceuticals, Inc.) USD 40.7 -3.26% · BHC (Bausch Health Companies Inc.) USD 6.44 -0.77% · HCM (HUTCHMED (China) Limited) USD 14.36 +0.56% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.2 -4.80% · RGC (Regencell Bioscience Holdings L) USD 7.67 -21.81% · LQDA (Liquidia Corporation) USD 42.65 +7.46%

## More
Full page: https://nexqual.com/PTPI · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter (ends 2025-03-31) | — | — | — | $0 | — |
| Current fiscal year (ends 2024-12-31) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |